

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS VII LLC,
Petitioner,

v.

POZEN INC.,
Patent Owner.

IPR2015-01241
Patent 6,926,907

PETITIONER'S EXHIBIT LIST

Pursuant to 37 C.F.R. § 42.63(e), Petitioner submits this current list of exhibits.

Exhibit No.	Description
1001	U.S. Patent No. 6,926,907 (“the ’907 Patent”)
1002	File History of the ’907 Patent
1003	Declaration of Leon Shargel, Ph.D., R.Ph.
1004	U.S. Patent No. 5,698,225 (“Gimet”)
1005	U.S. Patent No. 5,204,118 (“Goldman”)
1006	“Remington’s Pharmaceutical Sciences,” Alfonso R. Gennaro, et al., Mack Publ’g Co., Seventeenth Edition, 1985 (“Remington”)
1007	“Does Misoprostol Given as a Single Large Dose Improve its Antisecretory Effect?” S.G. Chiverton, et al., Aliment. Pharmacol. Therap., Vol. 3 (1989) (“Chiverton”)
1008	U.S. Patent No. 4,757,060 (“Lukacsko”)
1009	“The Mechanism of Action of Aspirin,” J.R. Vane, et al., Pergamon (2003)
1010	G.B. Patent No. 1211134
1011	“Drug-Induced Peptic Ulcer Disease,” Valerie Vella, Journal of the Malta College of Pharmacy Practice (2005)
1012	“Goodman & Gilman’s The Pharmacological Basis of Therapeutics,” Joel G. Hardman, et al., McGraw-Hill Publ’g Co., Ninth Edition (1996)
1013	U.S. Patent No. 6,365,184 (“Depui”)
1014	“Tagamet: The Discovery of Histamine H ₂ -Receptor Antagonists,” SmithKlein Beecham Pharms., Am. Chem. Soc. (Nov. 24, 1997)

Exhibit No.	Description
1015	“Inhibition of Gastric (H ⁺ + K ⁺)-ATPase by the Substituted Benzimidazole Picoprazole,” B. Wallmark, et al., <i>Biochimica et Biophysica Acta</i> , Vol. 728, at 31-38 (1983)
1016	U.S. Patent No. 4,255,431
1017	“Drug Discovery: Practices, Processes, and Perspectives,” Jie Jack Li, et al., John Wiley & Sons (Apr. 3, 2013)
1018	U.S. Patent App. Pub. 2002/0045184 (“Chen”)
1019	“Management of NSAID-Related Gastrointestinal Mucosal Injury,” A.F. Barrison, et al., <i>Inflammopharmacology</i> 7(3), at 277-86 (1999)
1020	“Prevention of NSAID-Induced Gastroduodenal Ulcers,” A. Rostom, et al., <i>Cochrane Database of Systematic Reviews</i> (2000)
1021	VIMOVO® (Naproxen and Esomeprazole Magnesium) Tablets Horizon Pharma, http://www.horizonpharma.com/vimovo/ (last visited May 9, 2015)
1022	Horizon Pharma plc 2014 Irish Statutory Accounts,” Horizon Pharma Public Limited Company (Apr. 9, 2015)
1023	Nov. 19, 2004 Amendment and Response Under 37 C.F.R. § 1.116, File History of the ’907 Patent
1024	“Pharmaceutical Companies Buy Rivals’ Drugs, Then Jack Up the Prices,” <i>The Wall Street Journal</i> (Apr. 26, 2015)
1025	Oct. 20, 2004 Final Office Action, File History of the ’907 Patent
1026	Nov. 19, 2004 Request for Continued Examination, File History of the ’907 Patent
1027	Mar. 29, 2005 Notice of Allowance and Fee(s) Due, File History of the ’907 Patent

Exhibit No.	Description
1028	Dec. 25, 2007 Certificate of Correction, File History of the '907 Patent
1029	“Clinical Trial: Evaluation of Gastric Acid Suppression with Three Doses of Immediate-Release Esomeprazole in the Fixed-Dose Combination of PN 400 (Naproxen/Esomeprazole Magnesium) Compared with Naproxen 500 mg and Enteric-Coated Esomeprazole 20 mg: A Randomized, Open-Label, Phase I Study in Healthy Volunteers,” Miner et al., <i>Alim. Pharmacol. Ther.</i> , 32:414-424 (2010) (“Miner”)
1030	Nexium 24HR Acid Reducer, 42 Capsules – Walmart.com, http://www.walmart.com/ip/Nexium-24HR-Acid-Reducer-42-Capsules/35284453 (last visited May 9, 2015)
1031	“Effects of Misoprostol on Gastric Acid and Mucus Secretion in Man,” Donald E. Wilson, et al., <i>Digestive Diseases and Sciences</i> , Vol. 31, No. 2 (Feb. 1986)
1032	“Misoprostol Versus Antacid Titration for Preventing Stress Ulcers in Postoperative Surgical ICU Patients,” Michael J. Zinner, MD, et al., <i>Ann. Surg.</i> , Vol. 210, No. 5 (Nov. 1989)
1033	“COX-2 Inhibitors,” Peter M. Brooks, et al., <i>Australian Prescriber</i> (Feb. 1, 2000)
1034	“Effect of Orally Administered Prostaglandin E2 and its 15-Methyl Analogues on Gastric Secretion,” Karim, et al., <i>British Med. Journal</i> (Jan. 20, 1973)
1035	“Effect of Increasing Gastric pH with Famotidine on the Absorption and Oral Pharmacokinetics of the Inotropic Agent Vesnarinone,” B. Koneru, et al., <i>J. Clin. Pharmacol.</i> (1998)

Exhibit No.	Description
1036	“Twenty-Four-Hour Intra-gastric pH Profiles and Pharmacokinetics Following Single and Repeated Oral Administration of the Proton Pump Inhibitor Pantoprazole in Comparison to Omeprazole,” M. Hartmann, et al., <i>Aliment Pharmacol. Ther.</i> (Jan. 3, 1996)
1037	“Effects of Famotidine on Gastric pH and Residual Volume in Pediatric Surgery.” J.S. Jahr, et al., <i>Acta Anaesthesiol Scand.</i> (1991)
1038	“Effect of Preanesthetic Famotidine on Gastric Volume and pH,” Takahiko Okuda, et al., <i>Journal of Anesthesia</i> , Vol. 2, Issue 1 (Mar. 1988)
1039	“Effect of Oral and Intramuscular Famotidine on pH and Volume of Gastric Contents,” Kazuo Abe, M.D., et al., <i>Anesth. Analg.</i> (1989) (“Abe”)
1040	“High-Viscosity HPMC as a Film-Coating Agent,” G. Maffione, et al., <i>Drug Dev. & Indus. Pharmacy</i> (1993)
1041	“Upper Gastrointestinal (GI) pH in Young, Healthy Men and Women,” Jennifer B. Dressman, et al., <i>Pharmaceutical Research</i> , Vol. 7, No. 7, 756-761 (1990)
1042	FDA Response to Horizon’s Citizen Petition
1043	Notice of Final Determination, In re: Patent Term Extension for U.S. Patent No. 6,143,771
1044	“Prevention of the Gastrointestinal Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs, Gregor J.E. Brown, et al., <i>Drug Safety</i> (6): 503-512 (December 21, 1999)
1045	“Abolition by Omeprazole of Aspirin Induced Gastric Mucosal Injury in Man,” T K Daneshmend et al., <i>Gut</i> , Vol. 31, 514-517 (1990) (“Daneshmend”)
1046	U.S. Patent No. 6,319,519

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.